Introduction {#s1}
============

Precision oncology aims to tailor the therapeutic strategy based on tumor\'s molecular alterations. Previous studies have suggested the validity of such approach in rare and ultra-rare tumor subtypes, including rare head and neck cancers; with the identification of targetable alterations in up to 93% of cases ([@B1]). Ameloblastomas are rare tumors, which often have a benign course. Metastatic evolution is extremely rare and there is no standard of care for patients in this setting.

Case Report {#s2}
===========

In November 2018, a 26-year old female was referred for hemoptysis and cough of several weeks\' duration. Her past medical history was significant for the diagnosis, at the age of 13 years, of an ameloblastoma of the right mandible (tooth 48) treated by surgery with clear margins and no evidence of locoregional relapse since then. A CT scan was performed which showed numerous bilateral nodules. The patient underwent a CT-guided percutaneous lung biopsy of one of these nodules. Histological examination was in favor of lung metastasis of ameloblastoma.

The patient was enrolled in our molecular screening program after signature of informed consent (Bergonié Institut Profiling study, NCT02534649) and gave also written informed consent for the publication of this case report. Next-generation sequencing of the metastatic tumor sample was performed as previously described and revealed the presence of a *BRAF* gene V600E mutation \[[Figure 1](#F1){ref-type="fig"}; ([@B2])\]. Given the lack of validated standard treatment for advanced ameloblastoma, the molecular tumor board recommended initiation of a BRAF-targeted therapy. The patient started treatment with dabrafenib (150 mg BID) combined with trametinib (2 mg QD). The first TEP-CT scan performed 12 weeks after treatment onset showed competed response according to RECIST and PERCIST criteria ([Figure 2](#F2){ref-type="fig"}). The patient is still doing well and in complete remission 30 weeks after treatment initiation.

![Histological features of ameloblastoma (**A**: low magnification, **B**: high magnification) and BRAF V600E gene mutation assessed by next-generation sequencing **(C)**.](fonc-09-01204-g0001){#F1}

![Sustained complete response to dabrafenib + trametinib in a patient with ameloblastoma metastatic to the lungs.](fonc-09-01204-g0002){#F2}

Discussion {#s3}
==========

The ameloblastoma is a histologically almost always benign odontogenic tumor of the jaw bones with a potential of locoregional recurrence ([@B3]). Distant metastases are extremely rare.

Anecdotal response has been reported with platinum salts agents but there is no standard of care in this setting ([@B4]). A seminal study investigating the molecular landscape of ameloblastomas revealed that ameloblastomas are characterized by the a frequent incidence of BRAF V600E mutations particularly in tumors located in the mandibular region while mutations of the SMO gene (39%) were predominant in maxillary tumors (82%) ([@B5]). This study and others provided a rationale to investigate BRAF targeting in patients with advance ameloblastoma. Previous case reports have suggested the clinical activity of BRAF inhibitor such as vemurafenib in patients with advanced ameloblastoma ([Table 1](#T1){ref-type="table"}). We opted here for the combination of a BRAF and MEK inhibitors. Indeed, several studies performed in melanomas, and other BRAF-driven malignancy, showed that acquired resistance to BRAF inhibitors frequently develops through reactivation of the mitogen-activated protein kinase (MAPK) pathway, resulting in limited progression-free survival ([@B10]) In addition, the use of BRAF inhibitors as single agent may induce the development of secondary skin tumors, originating from a paradoxical activation of the MAPK pathway in cells without a *BRAF* mutation ([@B10]). In melanomas, combining a BRAF inhibitor with a MEK inhibitor addresses the limitations of single-agent BRAF inhibitors and results in a significant delay in the emergence of resistance, with a longer overall than with BRAF inhibitor alone, as well as a decreased incidence of BRAF-inhibitor--induced skin tumors ([@B10]). The toxicity of such a combination profile is generally good with the most common adverse events being rash, pyrexia, asthenia, headache, nausea, and arthralgia ([@B11]). The complete response observed here illustrate the role of molecular profiling in complicate clinical situation of rare head and neck cancer and the potential benefit of BRAF-targeted therapy in ameloblastoma carrying *BRAF* V600E mutation.

###### 

Clinical reports of BRAF-targeting in advanced ameloblastoma.

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  **References**             **Clinical setting**   **Tumor stage**    **Treatment**             **Outcome**
  -------------------------- ---------------------- ------------------ ------------------------- ----------------------------------------------------
  Fernandes et al. ([@B6])   29 years old female    Locally advanced   Vemurafenib               Partial response\
                                                                                                 PFS not reached at 11 months after treatment onset

  Tan et al. ([@B7])         85 years old male      Locally advanced   Dabrafenib                Partial response

  Faden and Algazi ([@B8])   83 years old male      Locally advanced   Dabrafenib                Partial response\
                                                                                                 PFS not reached at 12 months

  Kaye et al. ([@B9])        40 years old male      Metastatic         Dabrafenib + trametinib   Partial response\
                                                                                                 Not reached at 5 months after treatment onset
  ---------------------------------------------------------------------------------------------------------------------------------------------------
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